ES2072851T3 - Anticuerpos monoclonales para receptores fc para inmunoglobulina g en fagocitos mononucleares humanos; anticuerpos bifuncionales; celulas efectoras especificas de una diana; macrofagos con diana fijada; e inmunoensayos. - Google Patents

Anticuerpos monoclonales para receptores fc para inmunoglobulina g en fagocitos mononucleares humanos; anticuerpos bifuncionales; celulas efectoras especificas de una diana; macrofagos con diana fijada; e inmunoensayos.

Info

Publication number
ES2072851T3
ES2072851T3 ES87305998T ES87305998T ES2072851T3 ES 2072851 T3 ES2072851 T3 ES 2072851T3 ES 87305998 T ES87305998 T ES 87305998T ES 87305998 T ES87305998 T ES 87305998T ES 2072851 T3 ES2072851 T3 ES 2072851T3
Authority
ES
Spain
Prior art keywords
antibody
receiver
union
target
bifunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87305998T
Other languages
English (en)
Inventor
Michael W Fanger
Paul M Guyre
Clark L Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Application granted granted Critical
Publication of ES2072851T3 publication Critical patent/ES2072851T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Abstract

SE HA DESCUBIERTO UN ANTICUERPO MONOCLONAL ESPECIFICO-RECEPTOR DE FC HUMANA JUNTO CON SU MODO DE PREPARACION. LA UNION DE ANTICUERPO AL RECEPTOR FC NO ES BLOQUEADA POR LA INMUNOGLOBULINA G HUMANA. EL ANTICUERPO SE UNE AL RECEPTOR FC DE AFINIDAD ELEVADA POR EL IGG EN MONOCITOS HUMANOS A UN RECEPTOR DISTINTO DE UNION DESDE EL SITIO DE UNION DE LIGANDO PARA EL FC. UN ANTICUERPO BIFUNCIONAL O UN HETEROANTICUERPO POSEE UNA REGION DE UNION ANTIGENA DERIVADA DE UN ANTICUERPO RECEPTOR ANTI-FC Y UNA REGION DE UNION ANTIGENA ESPECIFICA PARA UN EPITOPE OBJETO O CELULA; TAL ANTICUERPO PUEDE DIRIGIR UN MACROFAGO CUANDO ESTE ESTA LIGADO A LOS RECEPTORES FC DE LA SUPERFICIE DEL MACROFAGO. UN RECEPTOR EXPRESOR DE CELULA EFECTORA ESPECIFICA OBJETO PARA LA PORCION FG DE IGG TIENE UNA REGION DE UNION ANTIGENA DERIVADA DE UN ANTICUERPO RECEPTOR ANTI-FC Y OTRO ESPECIFICO PARA UNA CELULA OBJETO, Y EL CITADO HETEROANTICUERPO O BIFUNCIONAL ESTA LIGADO AL RECEPTOR DE FC DE LA CELULA EFECTORA; TAL CELULA EFECTORAPUEDE SER UTILIZADA EN LA TERAPIA DE CANCERES, ALERGIAS, ENFERMEDADES AUTOINMUNES O INFECCIOSAS, Y EN INMUNOENSAYOS.
ES87305998T 1986-07-07 1987-07-07 Anticuerpos monoclonales para receptores fc para inmunoglobulina g en fagocitos mononucleares humanos; anticuerpos bifuncionales; celulas efectoras especificas de una diana; macrofagos con diana fijada; e inmunoensayos. Expired - Lifetime ES2072851T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88218186A 1986-07-07 1986-07-07
US07/069,412 US4954617A (en) 1986-07-07 1987-07-01 Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes

Publications (1)

Publication Number Publication Date
ES2072851T3 true ES2072851T3 (es) 1995-08-01

Family

ID=26750030

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87305998T Expired - Lifetime ES2072851T3 (es) 1986-07-07 1987-07-07 Anticuerpos monoclonales para receptores fc para inmunoglobulina g en fagocitos mononucleares humanos; anticuerpos bifuncionales; celulas efectoras especificas de una diana; macrofagos con diana fijada; e inmunoensayos.

Country Status (10)

Country Link
US (1) US4954617A (es)
EP (2) EP0629703A3 (es)
AT (1) ATE120802T1 (es)
AU (1) AU605771B2 (es)
CA (1) CA1319899C (es)
DE (1) DE3751214T2 (es)
ES (1) ES2072851T3 (es)
IL (2) IL83113A0 (es)
NZ (1) NZ220973A (es)
WO (1) WO1988000052A1 (es)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071517A (en) * 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
US5635600A (en) * 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
CA1338518C (en) * 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
WO1989006544A1 (en) * 1988-01-15 1989-07-27 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
WO1991000360A1 (en) * 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
FR2653561A1 (fr) * 1989-10-19 1991-04-26 Fondation Nale Transfusion San Hetero-anticorps anti-rhd et composition pharmaceutique les contenant.
JPH05504677A (ja) * 1989-10-20 1993-07-22 トラスティーズ オブ ダートマス カレッジ ＩｇＡレセプターに特異的なモノクロナール抗体
JP3360108B2 (ja) 1989-10-20 2002-12-24 メダレックス インク． 二つのエフェクター機能を有する二元特異性異種抗体
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
WO1992005793A1 (en) * 1990-10-05 1992-04-16 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE153768T1 (de) * 1991-01-15 1997-06-15 Bayer Ag Ergänzung von oberflächenrezeptoren
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
US5994514A (en) * 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
AU5322494A (en) * 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5487975A (en) * 1993-11-15 1996-01-30 Ventana Medical Systems, Inc. Biotin/avidin formulation
DE69527050T2 (de) * 1994-03-07 2003-02-13 Medarex Inc Bispezifische moleküle mit klinischer verwendbarkeit
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
FI951778A (fi) * 1995-04-12 1996-10-13 Aboatech Ab Oy Menetelmä allergian toteamiseksi
US20030144483A1 (en) * 1995-05-04 2003-07-31 Medarex, Inc. Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
GB9509620D0 (en) * 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
EP0832134B1 (en) * 1995-06-07 2000-07-26 Medarex, Inc. Anti-allergy bispecific molecules
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
WO1998009647A2 (en) * 1996-09-06 1998-03-12 Medarex, Inc. Cyanidin compositions and therapeutic and diagnostic uses therefor
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6682928B2 (en) * 1997-12-02 2004-01-27 Medarex, Inc. Cells expressing anti-Fc receptor binding components
EA200000848A1 (ru) * 1998-02-17 2001-04-23 Медарекс, Инк. Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US20010051147A1 (en) * 2000-03-27 2001-12-13 Van De Winkel Jan G.J. Methods for immunostimulation using binding agents for the Fc receptor of immunoglobulin A
JP5007409B2 (ja) * 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション 樹状細胞に対するヒトモノクローナル抗体
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100497389C (zh) * 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20060068405A1 (en) * 2004-01-27 2006-03-30 Alex Diber Methods and systems for annotating biomolecular sequences
US20030077282A1 (en) 2001-10-12 2003-04-24 Bigler Michael Eric Use of bispecific antibodies to regulate immune responses
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP2330130B1 (en) 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
ATE552860T1 (de) * 2003-01-31 2012-04-15 Celldex Res Corp Antikörper-vakzine-konjugate und ihre verwendungen
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
US20050191293A1 (en) 2003-12-10 2005-09-01 Shrikant Deshpande IP-10 antibodies and their uses
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
KR101297146B1 (ko) 2004-05-10 2013-08-21 마크로제닉스, 인크. 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DK2662390T3 (da) 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20070014795A1 (en) * 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1960434B1 (en) 2005-12-08 2012-07-11 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
EP2021029B1 (en) 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
SI2081595T1 (sl) 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
US8450464B2 (en) 2006-10-02 2013-05-28 Medarex, Inc. Human monoclonal antibodies that bind CXCR4
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
TW200837081A (en) 2006-11-15 2008-09-16 Medarex Inc Human monoclonal antibodies to BTLA and methods of use
BRPI0717902A2 (pt) 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
PL2769729T3 (pl) 2007-09-04 2019-09-30 Compugen Ltd. Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
EP2570137A3 (en) * 2007-11-07 2013-08-21 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
CA2713055C (en) * 2008-01-25 2018-03-13 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CA2714071A1 (en) 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
CA2720368C (en) 2008-04-02 2017-08-22 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
DK2732823T3 (da) 2008-06-25 2019-09-16 H Lundbeck As Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2373690B1 (en) 2008-12-08 2015-02-11 Compugen Ltd. Antibodies specific for tmem154
EP3165537A1 (en) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
PL2403878T3 (pl) 2009-03-05 2017-12-29 E. R. Squibb & Sons, L.L.C. W pełni ludzkie przeciwciała specyficzne dla CADM1
EP2421898B1 (en) 2009-04-20 2016-03-16 Oxford BioTherapeutics Ltd Antibodies specific to cadherin-17
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
CA2791658C (en) 2010-03-04 2019-10-01 Macrogenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2552947A4 (en) 2010-03-26 2013-11-13 Dartmouth College VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
MY160826A (en) 2011-06-28 2017-03-31 Berlin-Chemie Ag Antibodies to bone marrow stromal antigen 1
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
BR112014018481A2 (pt) 2012-02-01 2017-07-04 Compugen Ltd anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
LT3055331T (lt) 2013-10-11 2021-03-25 Oxford Bio Therapeutics Limited Konjuguoti antikūnai prieš ly75, skirti vėžio gydymui
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
ITUB20155272A1 (it) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
SG11201808979UA (en) 2016-04-15 2018-11-29 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
BR112018073414A2 (pt) 2016-05-16 2019-08-27 Checkmab S R L molécula, composição farmacêutica, e, métodos in vitro para prognosticar e/ou diagnosticar e/ou avaliar o risco de desenvolver e/ou para monitorar a progressão e/ou para monitorar a eficácia de um tratamento terapêutico e/ou para a triagem de um tratamento terapêutico de um tumor, para tratar e/ou prevenir tumor e para identificar uma molécula.
EP3584258A1 (en) 2018-06-19 2019-12-25 IEO - Istituto Europeo di Oncologia Srl Antibodies anti tumor associated antigens and method for obtaining them
US20220229062A1 (en) * 2021-01-21 2022-07-21 Diagnostic Biosystems Method for rapid immunohistochemical detection of an antigen from a biological sample

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2322533C2 (de) * 1972-11-06 1986-08-28 Pharmacia AB, Uppsala Verfahren zum Binden von Immunoglobulin und Hilfsmittel zur Durchführung des Verfahrens
IL57108A (en) * 1979-04-22 1981-12-31 Yeda Res & Dev Assay for the quantitative determination of interferon and a kit therefor
WO1982001773A1 (en) * 1980-11-07 1982-05-27 Secher David S Assay for interferon
US4481298A (en) * 1981-04-13 1984-11-06 Amf Incorporated Pre-precipitated double antibody immunoassay method
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4479895A (en) * 1982-05-05 1984-10-30 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
CA1194415A (en) * 1982-05-05 1985-10-01 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
EP0094463A3 (en) * 1982-05-17 1985-08-21 Beta Instrument Company Limited Optical measuring apparatus
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
DE3404302C1 (de) * 1984-02-08 1985-06-05 Hermann Hemscheidt Maschinenfabrik Gmbh & Co, 5600 Wuppertal Steuervorrichtung fuer ein hydraulisches Schreitausbaugestell
JPH0736016B2 (ja) * 1984-05-11 1995-04-19 和光純薬工業株式会社 免疫グロブリンの定量方法
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0259585B1 (en) * 1986-07-29 1993-06-09 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for ige and hybrid cell lines producing these antibodies and use thereof

Also Published As

Publication number Publication date
DE3751214T2 (de) 1995-11-16
IL83113A (en) 1992-11-15
EP0255249A3 (en) 1990-03-07
WO1988000052A1 (en) 1988-01-14
ATE120802T1 (de) 1995-04-15
EP0629703A2 (en) 1994-12-21
CA1319899C (en) 1993-07-06
NZ220973A (en) 1989-11-28
US4954617A (en) 1990-09-04
EP0255249A2 (en) 1988-02-03
DE3751214D1 (de) 1995-05-11
AU7527187A (en) 1988-01-14
EP0255249B1 (en) 1995-04-05
AU605771B2 (en) 1991-01-24
EP0629703A3 (en) 1995-03-22
IL83113A0 (en) 1987-12-31

Similar Documents

Publication Publication Date Title
ES2072851T3 (es) Anticuerpos monoclonales para receptores fc para inmunoglobulina g en fagocitos mononucleares humanos; anticuerpos bifuncionales; celulas efectoras especificas de una diana; macrofagos con diana fijada; e inmunoensayos.
AU6054398A (en) Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
IL59917A (en) Monoclonal antibody of class igg to normal human t cells and cutaneous t lymphoma cells,its preparation and pharmaceutical and diagnostic compositions containing it
NO20020255L (no) Fc-fusjonsproteiner for forsterkning av immunogeniteten av protein- og peptidantigener
DK0595798T3 (da) Bispecifikke heteroantistoffer med dobbelte effektorfunktioner
DK0668924T3 (da) Humaniserede antistoffer mod Fc-receptorer for immunoglobulin G på humane mononukleare fagocytter
ES2152306T3 (es) Anticuerpos monoclonales reactivos con regiones definidas del receptor del antigeno de la celula t.
ATE171207T1 (de) Monoklonaler antikörper
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
KR880700823A (ko) 사이토메갈로 바이러스에 대한 사람.모노클로날 항체와 그 제조방법
DK0474691T3 (da) Monoklonale antistoffer til induktion af tolerance
ES2060581T3 (es) Anticuerpos monoclonales sobre receptor de interleuquina-2 humana.
ATE115412T1 (de) Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
YU46386B (sh) Monoklonska antitela i antigeni za ljudske karcinome pluća koji ne pripadaju tipu "malih ćelija"
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
ES2088464T3 (es) Uso y administracion de enzimas.
DK102589D0 (da) Antigen, der genkendes af mca 16-88
DK0537168T3 (da) Antigenet CTAA 28A32, som genkendes af MCA 28A32
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
DE69127043T2 (de) Menschliche monoklonale antikörper gegen gpiii des varizella-zoster-virus
SE9501302D0 (sv) Antibodies for use in cancertherapy and diagnosis
FI860936A (fi) Menetelmä ja reagenssi luteinisoivan hormonin määrittämiseksi sekä tähän tarkoitukseen sopivat monoklonaaliset vasta-aineet
BG50337A1 (en) Hybridom cellular line secreting a monoclonal anti-body against insulin
EP0089771A3 (en) Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 255249

Country of ref document: ES